Co-delivery of siRNA and doxorubicin to cancer cells from additively manufactured implants
Open Access
- 16 November 2015
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (123) , 101718-101725
Abstract
Tumors in load bearing bones are a major clinical problem as recurrence is common after surgery. Void filling scaffolds that kill residual cancer cells by releasing chemotherapy and siRNA/chitosan nanoparticles may offer a solution to this problem.Keywords
This publication has 53 references indexed in Scilit:
- Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA NanoparticlesMolecular Therapy Nucleic Acids, 2013
- Cdk2 Silencing via a DNA/PCL Electrospun Scaffold Suppresses Proliferation and Increases Death of Breast Cancer CellsPLOS ONE, 2012
- Fabrication and characterization of a rapid prototyped tissue engineering scaffold with embedded multicomponent matrix for controlled drug releaseInternational Journal of Nanomedicine, 2012
- Local Delivery of Chitosan/VEGF siRNA Nanoplexes Reduces Angiogenesis and Growth of Breast Cancer In VivoNucleic Acid Therapeutics, 2012
- Complications in the management of metastatic spinal diseaseWorld Journal of Orthopedics, 2012
- The use of BMP-2 coupled – Nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defectsBiomaterials, 2010
- siRNA Nanoparticle Functionalization of Nanostructured Scaffolds Enables Controlled Multilineage Differentiation of Stem CellsMolecular Therapy, 2010
- Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulationJournal of Controlled Release, 2010
- Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular SpheroidsAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- Origins and Mechanisms of miRNAs and siRNAsCell, 2009